
Cassel Salpeter & Co.’s Q3 healthcare update points to disrupted NIH grant processing, FDA attrition, and tariffs as pressures on drug development and early-stage financing.
To find all documents, a witness list, and video coverage from the hearing, “Institutional Review Boards that Oversee Experimental Human Testing for Profit,” held by the Subcommittee on Oversight and Investigations on Thursday, March 26, 2009, please visit






